Mycoses in AIDS

Medical Mycology

Volumn 38, Issue , 2000, Pages 259-267

  Dupont, B ^a   Brown, H H Crewe ^b   Westermann, K ^b,c   Martins, M D ^d,e   Rex, J H ^e   Lortholary, O ^f   Kauffmann, C A ^g  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f UNIVERSITÉ PARIS 13   (France)

^g VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Antifungal prophylaxis; Cryptococcosis; Endemic mycosis; Fluconazole resistant Candida

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; ATOVAQUONE; COTRIMOXAZOLE; DAPSONE; FLUCONAZOLE; ITRACONAZOLE; PENTAMIDINE; PYRIMETHAMINE; TERBINAFINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CONFERENCE PAPER; CRYPTOCOCCOSIS; DERMATITIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG RESPONSE; ENDEMIC DISEASE; HEALTH CARE COST; HIGH RISK POPULATION; HISTOPLASMOSIS; HUMAN; INCIDENCE; MAINTENANCE THERAPY; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PROPHYLAXIS; SOUTH AFRICA; SPOROTRICHOSIS; THRUSH;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MYCOSES;

CANDIDA; PNEUMOCYSTIS CARINII; RNA VIRUSES;

EID: 0034499303     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/mmy.38.s1.259.267     Document Type: Article

References (86)

1. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: Three San Francisco epidemiological cohorts
2. Oral candidiasis and human immunodeficiency virus infection
3. Epidemiology of oral candidiasis in HIV-infected patients: Colonization, infection, treatment, and emergence of fluconazole resistance
4. Infection due to fluconazole-resistant Candida in patients with AIDS: Prevalence and microbiology
5. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: Persistence of Candida albicans strains with the same genotype
6. Resistance of Candida species to fluconazole
7. Correlation of in vitro fluconazole resistance of Candida albicans in patients with recurrent oropharygenal candidosis and human immunodeficiency virus type 1
8. Fluconazole-resistant candidosis in an HIV cohort
9. Point prevalence of carriage of fluconazole-resistant Candida in the oropharynx of HIV-Infected patients
10. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients
11. Resistant candidiasis
12. Positive effects of combined antiretroviral therapy on CD4 T cell homeostasis and function in advanced HIV disease
13. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents
14. Improvement in cell-mediated immune functions during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir
15. Treatment of HIV-1 associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy
16. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir
17. Decline in CMV and other opportunistic disease with combination antiretroviral therapy
18. Update: Trends in AIDS incidence 1996
19. Recovery of the immune system with antiretroviral therapy: The end of opportunism?
20. Resolution of intractable molluscum contagiosum in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with ritonavir
21. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor
22. 2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy
23. Remission of progressive multifocal leukoencephalopathy following splenectomy and antiretroviral therapy in a patient with HIV infection
24. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
25. Changing patterns of mortality across Europe in patients infected with HIV-1. Euro-SIDA Study Group
26. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality
27. Effect of HAART on natural history of AIDS-related opportunistic disorders
28. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. Albicans in human immunodeficiency virus-infected patients
29. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors
30. Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy
31. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration: Multicenter AIDS cohort study investigators
32. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis
33. HIV protease inhibitors
34. HIV protease inhibitors
35. Candida albicans secreted aspartyl proteinases
36. Evidence for a correlation between proteinase secretion and vulvovaginal candidosis
37. Evidence that members of the secretory aspartyl proteinases gene family (SAP), in particular SAP2, are virulence factors for Candida vaginitis
38. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors
39. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients
40. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: A prospective case-control study
41. Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization
42. Acute human immunodeficiency virus type 1 infection
43. Human immunodeficiency virus 1 envelope protein gp120 impairs intracellular antifungal mechanisms in human monocytes
44. Human immunodeficiency virus type 1 gp160 and gp41 binding to Candida albicans selectively enhances candidal virulence in vitro
45. Immune reconstitution in HIV infection
46. Clinical and biological aspects of cryptococcosis in France
47. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection
48. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: Randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group
49. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection
50. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group
51. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use
52. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study
53. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1 infected patients treated with highly active antiretroviral therapy
54. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group
55. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators
56. Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: Incidence, risk factors, and prevention
57. Discontinuation of antifungal therapy for cryptococcosis after immunologic response to antiretroviral therapy
58. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome
59. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus
60. Endemic mycoses: A treatment update
61. Endemic mycoses in AIDS: A clinical review
62. Progressive disseminated histoplasmosis in patients with acquired immunodeficiency syndrome
63. Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: Incidence, risk factors, and pathophysiology
64. Disseminated histoplasmosis in the acquired immunodeficiency syndrome: Clinical findings, diagnosis, and treatment, and review of the literature
65. Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients
66. Coccidioidomycosis during human immunodeficiency virus infection: Results of a prospective study in a coccidioidal endemic area
67. Coccidioidomycosis in patients with human immunodeficiency virus, review of 91 cases at a single institution
68. Coccidioidomycosis among persons with AIDS in the United States
69. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome
70. Itraconazole maintenance treatment for histoplasmosis in AIDS: A prospective, multicenter trial
71. Opportunistic coccidioidomycosis in patients with human immunodeficiency virus prevention issues and priorities
72. A multicenter rendomized trial comparing amphotericin B and liposomal amphotericin B (AmBisome) as induction therapy of disseminated histoplasmosis in AIDS patients
73. Treatment of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome
74. In vitro susceptibility of Candida species to Fluconazole
75. Clinical and biochemical parameters in HIV positive patients with oesophageal candidiasis
76. Cryptococcal meningitis in Durban, South Africa: A comparison of clinical features, laboratory findings and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients
77. A ten year study of cryptococcal meningitis
78. Cutaneous cryptococcosis and Kaposi's sarcoma occurring in the same lesions in a patient with the acquired immunodeficiency syndrome
79. Histoplasmosis presenting with unusual skin lesions in acquired immunodeficiency syndrome
80. Disseminated histoplasmosis in a human immunodeficiency virus-infected African child
81. Disseminated histoplasmosis in AIDS patients in South Africa: A report of 3 cases and review
82. Cutaneous manifestations of human immunodeficiency virus infection
83. The clinical, therapeutic and epidemiological features of sporotrichosis infection on the mines
84. HIV disease and the skin. Part II